Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.8K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.1K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.1K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.6K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.6K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

568
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
568
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

762
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
762

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Second-Generation of Deuterium-Substituted Glutamate Uptake Enhancers Exhibit Superior Drug-Like Properties in Preclinical Evaluation.

ACS central science·2026
Same author

Dosage effect of copy number variation in epilepsy and ten regions of the human brain.

Scientific reports·2025
Same author

Genome-wide association meta-analyses of drug-resistant epilepsy.

EBioMedicine·2025
Same author

Plasma metabolomic signatures for copy number variants and COVID-19 risk loci in Northern Finland populations.

Scientific reports·2025
Same author

Seeding-competent early tau multimers are associated with cell type-specific transcriptional signatures.

Acta neuropathologica·2025
Same author

Cell state-dependent allelic effects and contextual Mendelian randomization analysis for human brain phenotypes.

Nature genetics·2025

Related Experiment Video

Updated: Jan 2, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.4K

A systems-level framework for anti-epilepsy drug discovery.

Michael R Johnson1, Rafal M Kaminski2

  • 1Department of Brain Sciences, Imperial College London, Room E419, Burlington Danes Building, Hammersmith Hospital Campus 160 Du Cane Road, London, W12 0NN, United Kingdom.

Neuropharmacology
|December 1, 2019
PubMed
Summary

A novel systems genetics approach identifies disease mechanisms for epilepsy drug discovery. This method integrates genetic risk and gene expression to find new anti-epilepsy drug targets.

Keywords:
Disease modificationDrug discoveryEpilepsyGene regulatory networkIntegrative genomicsNetworkRNA-seqRegulomeSingle-cellSystems geneticsTranscriptomicsscRNA-seqsnRNA-seq

More Related Videos

Author Spotlight: Advancing Genetic Epilepsy Studies with Multi-Electrode Array-Based Long-Term Electrophysiological Monitoring of Human Brain Assembloids
06:30

Author Spotlight: Advancing Genetic Epilepsy Studies with Multi-Electrode Array-Based Long-Term Electrophysiological Monitoring of Human Brain Assembloids

Published on: September 27, 2024

2.0K
Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy
08:26

Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy

Published on: October 19, 2021

6.2K

Related Experiment Videos

Last Updated: Jan 2, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.4K
Author Spotlight: Advancing Genetic Epilepsy Studies with Multi-Electrode Array-Based Long-Term Electrophysiological Monitoring of Human Brain Assembloids
06:30

Author Spotlight: Advancing Genetic Epilepsy Studies with Multi-Electrode Array-Based Long-Term Electrophysiological Monitoring of Human Brain Assembloids

Published on: September 27, 2024

2.0K
Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy
08:26

Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy

Published on: October 19, 2021

6.2K

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Modern anti-seizure drugs offer improved safety but not efficacy over older generations.
  • Advances in epilepsy genetics have not yet yielded more effective or disease-modifying therapies.
  • Severe monogenic epilepsies are gaining research interest, but translation to drug development is limited.

Purpose of the Study:

  • To introduce a novel systems genetics approach for identifying disease-modifying anti-epilepsy drugs.
  • To bridge the gap between genetic insights and the development of effective epilepsy treatments.
  • To present a flexible framework applicable to various diseases with available cell-type and disease-context data.

Main Methods:

  • Integrating polygenic risk with cellular gene expression profiles to identify pathophysiological mechanisms.
  • Utilizing a gene regulatory (regulome) framework to link molecular mechanisms to druggable targets.
  • Applying a systems genetics approach to epilepsy drug discovery.

Main Results:

  • The described approach facilitates the identification of novel disease-modifying anti-epilepsy drug candidates.
  • It provides a method to connect complex genetic information with potential therapeutic targets.
  • The framework is adaptable for drug discovery in other complex diseases.

Conclusions:

  • The systems genetics approach represents a promising new direction for anti-epilepsy drug discovery.
  • This methodology can accelerate the development of more effective treatments for epilepsy.
  • The approach is broadly applicable to diseases with relevant molecular and genetic data.